Abstract

Abstract

A decade ago, Pluronic lecithin organogel was developed by Marty Jones. His colleague Lawson Kloesel suggested adding Pluronic F127 to stabilize the original formula. In this interview, Jones describes the process of creating this base for transdermal preparations and explains how and why it is effective. Topics discussed include the way Pluronic lecithin organogel was developed, its mechanism of action, ways the first formulation was improved, its clinical evaluation, steps in defining its uses, drugs not appropriate for use in this vehicle, storage or preparations and its future as a transdermal vehicle. Sample formulations for transdermal compounds using Pluronic lecithin organogel are provided, including Ketoprofen 10% in PLO, ABHR in PLO, Ketamine Hydrochloride 10%, Gabapentin 6%, Clonidine Hydrochloride 0.2% in PLO, and Methimazole 5 mg/0.l mL in PLO (Veterinary Formulation).

Related Keywords

• ABHR in PLO
• Ketamine HCl 10%, gabapentin 6%, clonidine HCl 0.2% in PLO, formulation for
• Ketoprofen 10% in PLO, formulation for
• Methimazole 5 mg/0.1 mL in PLO (veterinary formulation)
• PLO, history of
• PLO, in transdermal gels, formulations for
• Pluronic lecithin organogel, history of

Related Categories

• DIABETES
• HISTORY
• PAIN MANAGEMENT